ArticleClinicoEconomics and outcomes research : CEOR2025
Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China.
Wenjuan Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.